|Application ||WB, IHC|
|Calculated MW||49880 Da|
|Other Names||Glial fibrillary acidic protein, GFAP, GFAP|
|Target/Specificity||A synthetic peptide corresponding to residues in the C-term of human GFAP was used as immunogen.|
|Format||50 mM Tris-Glycine (pH 7.4), 0.15 M NaCl, 40% Glycerol, 0.01% sodium azide and 0.05% BSA.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.|
|Precautions||GFAP Antibody (C-term) is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||GFAP, a class-III intermediate filament, is a cell- specific marker that, during the development of the central nervous system, distinguishes astrocytes from other glial cells.|
|Cellular Location||Cytoplasm. Note=Associated with intermediate filaments|
|Tissue Location||Expressed in cells lacking fibronectin.|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Glial fibrillary acidic protein (GFAP) belongs to the class III of the intermediate filament (IF) proteins highly specific to astrocytes which function as nerve cells in the brain and in the central nervous system (CNS) (1-2). Two other class III IF proteins, nestin and vimentin, dominate in immature astrocytes, while GFAP is most abundant in mature astrocytes (3). GFAP is used as a marker to distinguish astrocytes form other glial cells during development. Mutations in GFAP cause Alexander disease, a rare disorder of the CNS. Most frequent mutations are located at Arginine 79 or 239 (4).
1. Reeves, S. A.; Helman, L. J.; Allison, A.; Israel, M. A. : Proc. Nat. Acad. Sci. 86: 5178-5182, 1989.
2. Fuchs, E., and Weber, K. (1994) Annu. Rev. Biochem. 63, 345-382
3. Bongcam-Rudloff, E., Nister, M., Betsholtz, C., Wang, J. L., Stenman, G., Huebner, K., Croce, C. M., and Westermark, B. (1991) Cancer Res. 51, 1553-1560
4. Li et all. Ann. Neurol. 57: 310-326, 2005.
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.